News & Podcast
Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.
Sedivention secures €2.9 million in seed funding
The medtech startup Sedivention has completed a €2.9 million seed funding round led by bmp Ventures with the IBG Fonds. With the capital, the company plans to further develop a minimally invasive outpatient therapy for obesity and generate initial clinical data for its planned market entry.
€800,000 pre-seed funding for Sedivention
Early-stage investor High-Tech Gründerfonds (HTGF) invests €800,000 in Sedivention as part of a pre-seed funding round. The medtech startup develops a medical device that enables a one-time, interventional, and minimally invasive therapy for obesity.
Sedivention: novel therapy for obesity
The Munich medtech company Sedivention wants to simplify obesity treatment with a novel catheter – an approach with which the company has already convinced, among others, this year’s Munich Business Plan Competition. How the startup, founded in 2021 by Ute Nollert, Stéphane Delaloye, and André Burch, plans to combat the ‘hunger nerve’ and why this treatment method could become a real game changer for those affected, is reported by the founders in the interview.